Cascade Pharmaceuticals, Inc
Clinical trials sponsored by Cascade Pharmaceuticals, Inc, explained in plain language.
-
New hope for PBC patients: experimental drug CS0159 enters Mid-Stage trial
Disease control OngoingThis study tests an experimental drug called CS0159 in 75 adults with primary biliary cholangitis (PBC), a chronic liver disease. The goal is to see if the drug is safe and can improve liver health markers like ALP levels. Participants receive either CS0159 or a placebo for 12 we…
Phase: PHASE2 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated May 26, 2026 03:23 UTC
-
New MASH drug enters human testing – first safety check underway
Disease control OngoingThis early-stage study tests a new drug called CS060304 in healthy volunteers and people with high LDL-C (bad cholesterol) to see if it is safe and how the body processes it. The drug is being developed for MASH, a serious liver disease. About 80 participants will receive either …
Phase: PHASE1 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated May 26, 2026 03:16 UTC
-
New hope for rare liver disease: experimental drug CS0159 enters phase 2 trial
Disease control OngoingThis study tests a new drug called CS0159 in 50 adults with primary sclerosing cholangitis (PSC), a rare liver disease. The goal is to see if the drug is safe and can improve liver health by lowering certain liver enzyme levels. Participants will receive either CS0159 or a placeb…
Phase: PHASE2 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated May 15, 2026 11:56 UTC